{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tang Y"],"funding":["National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)"],"pagination":["431"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11906602"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Our study elucidates the role of FOXP1 in chemoresistance in small cell lung cancer(SCLC). FOXP1 enhances chemoresistance by regulating SP8 expression through its super-enhancer (SP8-SE), with SP8 mediating resistance via the homologous recombination repair (HRR) pathway. We also discovered that FOXP1 forms punctate nuclear structures indicative of liquid-liquid phase separation, crucial for its transcriptional regulation. Targeting the FOXP1-SP8-HR axis with BRD4 and PARP inhibitors showed synergistic effects in reducing tumor growth in vitro and in patient-derived xenograft models. These findings identify FOXP1 as a critical mediator and marker of chemoresistance in SCLC, providing a foundation for developing targeted therapies to overcome this resistance."],"journal":["Communications biology"],"pubmed_title":["Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance."],"pmcid":["PMC11906602"],"funding_grant_id":[",82172769"],"pubmed_authors":["Sun L","Xiong Y","Guo L","Hu Y","Wang Q","Chen Y","Wang Y","Zhou X","Tang Y","Niu Y","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Targeting FOXP1 phase separation in small cell lung cancer mechanisms of chemotherapy resistance.","description":"Our study elucidates the role of FOXP1 in chemoresistance in small cell lung cancer(SCLC). FOXP1 enhances chemoresistance by regulating SP8 expression through its super-enhancer (SP8-SE), with SP8 mediating resistance via the homologous recombination repair (HRR) pathway. We also discovered that FOXP1 forms punctate nuclear structures indicative of liquid-liquid phase separation, crucial for its transcriptional regulation. Targeting the FOXP1-SP8-HR axis with BRD4 and PARP inhibitors showed synergistic effects in reducing tumor growth in vitro and in patient-derived xenograft models. These findings identify FOXP1 as a critical mediator and marker of chemoresistance in SCLC, providing a foundation for developing targeted therapies to overcome this resistance.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-05-29T17:03:37.893Z","creation":"2026-04-08T05:27:39.186Z"},"accession":"S-EPMC11906602","cross_references":{"pubmed":["40082538"],"doi":["10.1038/s42003-025-07804-7"]}}